Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immucor appoints new CEO as De Chirico retires

This article was originally published in Clinica

Executive Summary

Gioacchino De Chirico is retiring from his role as president and CEO of blood screening firm Immucor after 18 years with the company. He will be immediately replaced by Joshua Levine, who was most recently president and CEO of aesthetic medical device developer Mentor; Mentor was acquired by Johnson & Johnson in 2009 (www.clinica.co.uk, 19 January 2009). Mr Levine has also worked for Kinetic Concepts, American Hospital Supply Corporation, and Baxter International. During his tenure, Dr De Chirico guided Norcross, Georgia-based Immucor through several scandals: in 2009, the FDA threatened to revoke its biologics licence over concerns about its manufacturing processes (www.clinica.co.uk, 30 June 2009); the company was also investigated for potential anti-competitive practices (www.clinica.co.uk, 28 April 2009).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel